Welcome to ATCGbio Life Technology Inc.

Advancing Life Sciences Technology

sh-LTviral-CAB39 (Calcium binding protein 39) Lentiviral Particle (SH3001-02)

Availability: In stock


Quick Overview

sh-LTviral-CAB39 (cat#SH3001-02) is the function-validated shRNA-CAB39 (Calcium binding protein 39) lentivirus particle.
The shRNA lentivirus particle product contains 3-tubes: 
a). Negative-control shRNA lentivirus particel  9.0ml, up to 0.9 x 108 TU/ml
b). sh-LTviral-CAB39 lentivirus particle   9.0ml, up to 0.9 x 108 TU/ml
c). Lenti-Storage Solution(reconstitution) 1.0ml, shipped at room temperature, store at 4ºC.
CAB39 also has been known as MO25 (Mouse Protein-25).
The total price for the first order is $350.00. From the second time order, the same target and control only cost $200.00.
Please CONTACT US by fill-in your fist-time order number, date and contact information including name, email, phone and address. We will provide you a second order code.

sh-LTviral-CAB39 (Calcium binding protein 39) Lentiviral Particle (SH3001-02)


                           Produtct Name:         shRNA-CAB39 Lentivirus Particle
        Official Gene Symbol:
        Gene ID:         51719  
        Official Full Name:         Calcium binding protein 39  
        Also Known As:         MO25; CGI-66  
        Target Species:         Human
        Product Validation:         shRNA Function validated  
        Technique Information:         User Manual PDF | MSDS PDF  
        Product Size:         9.0ml, store at -20°C  
        Product Category:         RNAi, Cat#3001-02  
        Price (USD):         $350.00  

Lentivirus plasmids will be shipped in 0.5 ml tube, and users are free to amplify. Upon receiving the tubes, keep it at 4 °C till amplification.

CAB39 protein, also known as mouse protein-25 (MO25), a scaffold protein, isoforms bind to the STRAD pseudokinase and stabilize it in a conformation that can activate the LKB1 tumour suppressor kinase. CAB39/MO25 has been addressed to be a novel regulatory component of the LKB1 complex that was found to interact with STRAD to play a crucial role in allowing LKB1 to phosphorylate and activate AMPK.

CAB39/MO25 has roles beyond controlling LKB1.These new CAB39/MO25 targets are SPAK/OSR1 kinases, regulators of ion homeostasis and blood pressure, and MST3/MST4/YSK1, involved in controlling development and morphogenesis.MO25α and MO25β associate with these STE20 kinases in a similar manner to STRAD. MO25 isoforms induce approximately 100-fold activation of SPAK/OSR1 dramatically enhancing their ability to phosphorylate the ion cotransporters NKCC1, NKCC2 and NCC, leading to the identification of several new phosphorylation sites. siRNA-mediated reduction of expression of CAB39/MO25 isoforms in mammalian cells inhibited phosphorylation of endogenous NKCC1 at residues phosphorylated by SPAK/OSR1, which is rescued by re-expression of MO25α. MO25α/β binding to MST3/MST4/YSK1 also stimulated kinase activity three- to four-fold. CAB39/MO25 has evolved as a key regulator of a group of STE20 kinases and may represent an ancestral mechanism of regulating conformation of pseudokinases and activating catalytically competent protein kinases (EMBO J.2011 May 4;30(9):1730-41)

ATCGbio Life Technology offers shRNA Lentivirus particle solutions which are recombinant shRNA expression lentivirus particle to be ready to infect directly for knocking-down gene of interest. It’s specifically designed for scientists who don’t have time or don’t prefer to make lentivirus by themselves. It’s the easiest way to knockdown gene of interest.

shRNA-Lenti particle from ATCGbio Life Technology are created base on safer 3rd. generation recombinant lentivirus vector through our new shRNA design system; and produced by our own Lentivirus Production Kit (LT1001). Virus expresses shRNA for target gene, GFP protein and hygromycine resistance gene product. It is suitable for both cultured cells and in vivo injection to small animals.  Lentivirus solution is DMEM based medium containing 2% FBS and our lentivirus precipitation/purification solution. It does not contain any chemicals used to boost lentivirus titers such as chloroquin, acetate or nicotines. The solution can be used directly to the cells growing in DMEM base medium without further precipitation/purification. There is no visible viral toxicities (e.g. change in cell morphology or/and cell detachment from culture plate) if the viral solution added up to a half amount of cell culture medium as described in table 1. Some special cells such as keratinocytes may be used to grow with special medium which is incompatible with DMEM or FBS. In such a case, it is recommended to precipitate/purify lentivirus and reconstitute it with storage solution as described in User Manual.

The highlight features of the products are:

1. Most advanced shRNA design.No need to add polybrene.Near 100% transduction (Fig.1.).
2. High infectious efficiency(Fig.2.), up to 0.9 x 108 TU/ml.
3. Co-express GFP protein and hygromycine resistance gene.
4. Just add and incubate overnight (16 hrs).
5. No cytotoxicity. Injectable to small animal without immonoreactive symptoms.
6. Unlike siRNA, transduced cells show knock-down effect in both dividing and nondividing cells.
7. Cell-line can be made in a week.
8. Suitable for both primary cells and transformed cells.

Our lentivirus particle will be shipped in propriety solution making high transduction without polybrene and unprecedented stability:

• Virus solution can be stored at -20 °C.
• Allow freezing and thawing up to 2 times.
• Be stable in room temperature at least 3-4 days.
• If necessary (the cells are incompatible with DMEM base medium), purification is easy as just centrifuge for 30min at 1500 × g.


                           Size of Culture          Culture Medium         Lentiviral Solution      
  1 well of 6-well plate 1.0ml 0.5ml
  1 well of 12-well plate 0.5ml 0.25ml
  1 well of 24-well plate 0.25ml 0.125ml
Fig.1. HepG2 cells grown in 100µl MEM+10% FBS on the 96-well plate were infected with 50µl shRNA lentivirus solution 48hrs.
Near 100% transduction.
Fig.2. 64hrs after infection without antibiotic selection, the target gene mRNAs were down to 28.8% in average of 10 shRNA targets in HepG2 cells.
More details are described below.

shRNA-lentivirus-performance                                           Non-target Gene-specific                           shRNA        shRNA

As shown in Figure 2. Ten transcription factors expressed in HepG2 cells were selected for this experiment. The lentivirus plasmids expressing shRNA were made for each target gene using our propriety design scheme (One shRNA sequence was selected for one target in each design). Lentivirus was created in 12-well plates using our Lentivirus Production kit, which produces a high titer stable lentivirus solution in 48hrs. HepG2 cells were grown in 96-well palate and infected with each virus including negative control shRNA by adding 50µl crude virus solution into HepG2 cells cultured with100µl culture medium for overnight(16hrs.). The cells were incubated further 48hrs., and harvested for Direct RT real-time PCR.  As shown in the right figure, 64 hrs. after infection, target gene mRNAs were down to 28.8% in average of 10 shRNA targets (p<0.0001 by paired t-test). 9 out of 10 design shRNA were able to suppress more than 70%, and only one out of 10 shRNA suppressed more modestly about 60%. Suppression will be greater, when the cells would be cultured longer time with antibiotics selection.


  1. Y. Ido, et al. PLoS ONE, 2012 Apr 07(4): e35092
  1. Lan F, et al.  J Biol Chem. 2008 Oct 10;283(41):27628-35


Related Products

Custom-made shRNA Lentivirus Particle

Lentivirus Production kit

Lentivirus Plasmids

Pre-made shRNA Lentivirus Plasmids

Custom-made shRNA Lentivirus Plasmids

RT-Real Time PCR Primer

Product Tags

Use spaces to separate tags. Use single quotes (') for phrases.